Business Context and Reporting Period
Company: Oscar Health, Inc. (OSCR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Oscar is a healthcare technology company offering health plans through the Affordable Care Act (ACA) individual market and providing technology solutions via its +Oscar platform. As of December 31, 2024, the company served approximately 1.68 million effectuated members across 18 states. The company exited the Medicare Advantage market prior to the 2024 plan year and ceased offering small group products as of December 15, 2024, including the non-renewal of its Cigna+Oscar partnership.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $9,177.6 million | $5,862.9 million |
| Premium Revenue | $8,971.3 million | $5,686.1 million |
| Net Income (Loss) | $26.1 million | ($270.6 million) |
| Net Income Attributable to Oscar | $25.4 million | ($270.7 million) |
| Adjusted EBITDA | $199.2 million | ($45.2 million) |
| Medical Loss Ratio (MLR) | 81.7% | 81.6% |
| SG&A Expense Ratio | 19.1% | 24.3% |
| Cash and Cash Equivalents | $1,527.2 million | $1,870.3 million |
| Total Investments | $2,439.7 million | $1,055.1 million |
| Long-Term Debt (2031 Notes) | $299.6 million | $298.8 million |
| Statutory Capital & Surplus (Subsidiaries) | $1,242.7 million | $800.6 million |
Material Changes vs. Prior Period
- Profitability Milestone: The company achieved its first-ever consolidated net income ($26.1 million) and positive Adjusted EBITDA ($199.2 million) for the full year, reversing a net loss of $270.6 million in 2023.
- Revenue Growth: Total revenue increased 56.5% year-over-year, driven primarily by a 58% increase in premium revenue due to higher membership (1.68 million vs. 1.04 million in 2023) and strong retention.
- Membership Expansion: Individual and Small Group membership grew to 1.64 million from 967,000. The company exited the Medicare Advantage market (0 members in 2024 vs. 1,781 in 2023) and reduced Cigna+Oscar membership to 40,570 from 67,500.
- Expense Management: While medical expenses rose 58% to $7.33 billion due to membership growth, the SG&A expense ratio improved significantly by 520 basis points to 19.1%, reflecting fixed cost leverage and variable cost efficiencies.
- Investment Portfolio: Total investments more than doubled to $2.44 billion from $1.06 billion, reflecting a larger asset base and higher investment income ($185.7 million vs. $155.4 million).
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Strategic Focus: Management emphasizes running sustainable operations, investing in member experience, and expanding the individual market through Individual Coverage Health Reimbursement Arrangements (ICHRA).
- Regulatory Environment: The company notes that enhanced Advanced Premium Tax Credits (APTC) are set to expire at the end of 2025. Failure to renew these subsidies could reduce marketplace participation and impact membership. Additionally, CMS has increased scrutiny on enrollment integrity, which may slow enrollment pace.
- Capital Position: Insurance subsidiaries exceeded minimum statutory Risk-Based Capital (RBC) requirements by approximately $774 million as of December 31, 2024. The company utilized quota share reinsurance to optimize capital efficiency.
Risks and Contingencies
- Regulatory Changes: Significant exposure to changes in the ACA, including potential repeal or modification of subsidies and risk adjustment programs.
- Medical Cost Volatility: Profitability depends on accurately estimating medical expenses. Unfavorable development in claims or changes in market morbidity could materially impact results.
- Reinsurance Dependency: The company relies on quota share reinsurance to meet capital requirements. If regulators do not approve these arrangements or terms become unfavorable, the company may need to fund significant additional capital (estimated at $553.8 million without reinsurance).
- Legal Proceedings: The company is subject to a securities class action lawsuit regarding its IPO registration statement and risk adjustment data validation. The outcome is uncertain and could result in material damages.
- Convertible Notes: The 2031 Convertible Senior Notes ($305 million principal) became convertible in Q1 2025 as the stock price condition was met. Holders may require repurchase upon a fundamental change.
Key Facts for Investor Verification
- First-Time Profitability: Verify the sustainability of the $26.1 million net income and $199.2 million Adjusted EBITDA, noting the reversal from a $270 million loss in 2023.
- Membership Quality: Assess the impact of Special Enrollment Period (SEP) growth on the Medical Loss Ratio (MLR), which increased slightly to 81.7%.
- Subsidy Expiration: Monitor the potential impact of the expiration of enhanced APTC subsidies at the end of 2025 on future enrollment and revenue.
- Capital Adequacy: Confirm the continued regulatory approval of quota share reinsurance arrangements, which are critical to maintaining the company's capital position without additional equity injections.
- Debt Convertibility: Track the conversion or repurchase activity of the $305 million 2031 Convertible Senior Notes, which are now convertible at the option of holders.
- Legal Exposure: Review updates on the Carpenter v. Oscar Health, Inc. securities class action lawsuit regarding IPO disclosures.